These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36601885)

  • 1. The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society.
    Wełnicki M; Gorczyca-Głowacka I; Mamcarz A; Filipiak KJ; Wożakowska-Kapłon B; Barylski M; Szymański FM; Kasprzak JD; Grabowski M; Dzida G
    Kardiol Pol; 2022; 80(12):1286-1289. PubMed ID: 36601885
    [No Abstract]   [Full Text] [Related]  

  • 2. [Heart and diabetes : What is the importance of GLP-1 receptor agonists in cardiology?].
    Moellmann J; Lehrke M
    Herz; 2022 Oct; 47(5):434-441. PubMed ID: 35857081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
    Grieve DJ; Cassidy RS; Green BD
    Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
    Wroge J; Williams NT
    Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function.
    Saraceni C; Broderick TL
    Drugs R D; 2007; 8(3):145-53. PubMed ID: 17472410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
    Anagnostis P; Athyros VG; Adamidou F; Panagiotou A; Kita M; Karagiannis A; Mikhailidis DP
    Diabetes Obes Metab; 2011 Apr; 13(4):302-12. PubMed ID: 21205117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society.
    Gorczyca-Głowacka I; Wełnicki M; Mamcarz A; Filipiak KJ; Wożakowska-Kapłon B; Barylski M; Szymański FM; Kasprzak JD; Tomasiewcz K
    Kardiol Pol; 2023; 81(2):207-214. PubMed ID: 36866400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor.
    Higashi Y
    J Cardiol; 2017 Mar; 69(3):508-510. PubMed ID: 27986341
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of glucagon-like peptide 1 on cardiovascular risk.
    Sivertsen J; Rosenmeier J; Holst JJ; Vilsbøll T
    Nat Rev Cardiol; 2012 Jan; 9(4):209-22. PubMed ID: 22290234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.
    Janez A; Muzurovic E; Stoian AP; Haluzik M; Guja C; Czupryniak L; Duvnjak L; Lalic N; Tankova T; Bogdanski P; Papanas N; Nunes JS; Kempler P; Fras Z; Rizzo M
    Int J Cardiol; 2022 Oct; 365():8-18. PubMed ID: 35905827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
    Beck-Nielsen H
    Ugeskr Laeger; 2012 Jun; 174(23):1606-8. PubMed ID: 22673382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.
    Tykarski A; Widecka K; Narkiewicz K; Wożakowska-Kapłon B; Gaciong Z; Grajek S; Grodzicki T; Januszewicz A; Wolf J; Prejbisz A; Kostka-Jeziorny K; Filipiak KJ
    Kardiol Pol; 2017; 75(12):1357-1367. PubMed ID: 29251761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence.
    Tsai SF; Chen CH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of GLP-1 receptor agonism.
    Winquist RJ; Gribkoff VK
    Adv Pharmacol; 2022; 94():213-254. PubMed ID: 35659373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.
    Tate M; Chong A; Robinson E; Green BD; Grieve DJ
    Br J Pharmacol; 2015 Feb; 172(3):721-36. PubMed ID: 25231355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits.
    Salem AM; Bain SC; Obaid DR
    Atherosclerosis; 2022 Jul; 352():83-84. PubMed ID: 35662526
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
    Verge D; López X
    Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
    Kielgast U; Holst JJ; Madsbad S
    Curr Diabetes Rev; 2009 Nov; 5(4):266-75. PubMed ID: 19925391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.